614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Measurable Residual Disease in Diagnosis and Prognosis: Poster II

Impact of IKZFplus status and ABL1 kinase domain mutations in patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia receiving imatinib and chemotherapy followed by allogeneic SCT within GMALL07 03

The impact of first line tyrosine kinase inhibitors TKI on the development of resistance mutations in patients with Philadelphia chromosome positive acute lymphoblastic leukemia Ph ALL

Immunophenotypic identification of ETP like T ALL using CD1a CD165 and CD184

Adverse genetic alterations and their prognostic impact in Chinese b ALL patients with DUX4 rearrangement

Synergistic integration of CAR T cell pharmacokinetics and NGS MRD evolution enables precision risk stratification in relapsed refractory B cell acute lymphoblastic leukemia

AP 3 targets the mrgbp Tip60 MYC axis to exert potent anti T ALL effects in a Notch1 independent manner

Evaluating flow cytometry FC and next generation sequencing NGS for assessing minimal residual disease MRD and B cell aplasia BCA in children adolescents and young adults CAYA with B cell acute lymphoblastic leukemia B ALL

Simvastatin targets the cholesterol–bile acid axis to improve ALL survival by remodeling the metabolic microenvironment